Inovio Pharmaceuticals (INO) Rises on Zika Trial

Inovio Pharmaceuticals Inc INO shares rose 3.1% to $10.79. Inovio Pharmaceuticals and GeneOne Life Science reported that they have received approval for first-in-man Zika vaccine clinical trial. Share volume was 812,000, compared to an all-day average of 1.7 million